Group 1 - The core viewpoint of the article indicates that International Medical (000516) is expecting significant losses in its financial performance for the year 2025, with projected net losses widening compared to the previous year [1][3] Group 2 - As of January 26, 2026, International Medical's stock closed at 5.16 yuan, down 0.96%, with a turnover rate of 3.28%, trading volume of 722,700 shares, and a transaction amount of 373 million yuan [1] - On January 26, the net inflow of main funds was 1.6254 million yuan, while retail investors showed a net inflow of 5.3559 million yuan, indicating mixed investor sentiment [1][3] Group 3 - The company forecasts a net profit loss attributable to shareholders of 295 million to 315 million yuan for 2025, which is an increase in losses compared to the previous year's loss of 254.1285 million yuan [1][3] - The expected operating revenue for 2025 is projected to be between 4.06 billion and 4.08 billion yuan, a decline from the previous year's revenue of 4.8154668 billion yuan, primarily due to market fluctuations and changes in DRG payment policies [1][3]

格隆汇1月26日丨国际医学(000516.SZ)在投资者互动平台表示，公司目前与阿里巴巴暂不涉及AI诊断方 面的合作。 ...

Group 1 - The core viewpoint of the article highlights the financial performance and stock activity of Guo Ji Yi Xue (International Medicine), indicating a decline in revenue and profit for the third quarter of 2025 [2] - As of January 26, 2026, the stock price closed at 5.16 yuan, down 0.96%, with a turnover rate of 3.28% and a trading volume of 722,700 hands, amounting to a total transaction value of 373 million yuan [1] - The company reported a main revenue of 2.995 billion yuan for the first three quarters of 2025, a year-on-year decrease of 16.94%, and a net profit attributable to shareholders of -294 million yuan, down 38.45% year-on-year [2] Group 2 - In the third quarter of 2025, the company recorded a single-quarter main revenue of 961 million yuan, a year-on-year decline of 18.95%, and a net profit attributable to shareholders of -129 million yuan, a significant drop of 234.24% year-on-year [2] - The company has a debt ratio of 68.8%, with investment income of 20.7586 million yuan and financial expenses of 111 million yuan, resulting in a gross profit margin of 6.59% [2] - Over the past 90 days, two institutions have given a rating of "buy" for the stock, with an average target price of 5.5 yuan [3]

Core Viewpoint - International Medical (000516) forecasts a net profit loss of between -295 million to -315 million yuan for 2025, representing a year-on-year decline of 16.08% to 23.95% [1] Group 1: Financial Performance - The company expects a significant decrease in net profit for 2025, indicating ongoing financial challenges [1] - The anticipated loss is attributed to market fluctuations and reforms in the DRG payment policy, which have negatively impacted revenue [1] Group 2: Operational Adjustments - In response to the adverse conditions, the company is adjusting its business structure and implementing cost reduction and efficiency improvement measures [1] - Despite these efforts, the total revenue generated in the fourth quarter has not yet covered operational costs and period expenses [1]

经济观察网 2026年1月26日，国际医学(000516)发布2025年度业绩预告，预计2025年净利润亏损3.15亿 元至2.95亿元，同比下降16.08%至23.95%；扣除非经常性损益后的净利润亏损3.5亿元至3.2亿元，同比 下降11.53%至21.98%。 ...

Core Viewpoint - International Medical is expected to report a net profit loss of between 295 million yuan and 315 million yuan for the full year of 2025 due to market fluctuations and DRG payment policy reforms impacting revenue [1] Financial Performance - For the first three quarters of 2025, the company's main revenue was 2.995 billion yuan, a year-on-year decrease of 16.94% [1] - The net profit attributable to shareholders was -294 million yuan, down 38.45% year-on-year [1] - The net profit excluding non-recurring items was -312 million yuan, a decline of 41.94% year-on-year [1] - In the third quarter of 2025, the company's single-quarter main revenue was 961 million yuan, a year-on-year decrease of 18.95% [1] - The single-quarter net profit attributable to shareholders was -129 million yuan, a significant drop of 234.24% year-on-year [1] - The single-quarter net profit excluding non-recurring items was -123 million yuan, down 52.03% year-on-year [1] Operational Metrics - The company's debt ratio stands at 68.8% [1] - Investment income reported was 20.7586 million yuan [1] - Financial expenses amounted to 111 million yuan [1] - The gross profit margin is recorded at 6.59% [1]

报告期内，公司受市场波动、DRG支付政策改革等行业动态调整影响，营业收入同比下降。公司采取 调整业务结构，实施降本增效等措施并持续改善经营成效，第四季度亏损幅度收窄，但营业收入总规模 尚未能覆盖运营成本和期间费用。 国际医学2025年三季报显示，前三季度公司主营收入29.95亿元，同比下降16.94%；归母净利润-2.94亿 元，同比下降38.45%；扣非净利润-3.12亿元，同比下降41.94%；其中2025年第三季度，公司单季度主 营收入9.61亿元，同比下降18.95%；单季度归母净利润-1.29亿元，同比下降234.24%；单季度扣非净利 润-1.23亿元，同比下降52.03%；负债率68.8%，投资收益2075.86万元，财务费用1.11亿元，毛利率 6.59%。 证券之星消息，国际医学发布业绩预告，预计2025年全年营业收入40.6亿元至40.8亿元。 公告中解释本次业绩变动的原因为： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，国际医学发布业绩预告，预计2025年全年扣除后营业收入:390,500万元至392,500万元。 公告中解释本次业绩变动的原因为： 报告期内，公司受市场波动、DRG支付政策改革等行业动态调整影响，营业收入同比下降。公司采取 调整业务结构，实施降本增效等措施并持续改善经营成效，第四季度亏损幅度收窄，但营业收入总规模 尚未能覆盖运营成本和期间费用。 国际医学2025年三季报显示，前三季度公司主营收入29.95亿元，同比下降16.94%；归母净利润-2.94亿 元，同比下降38.45%；扣非净利润-3.12亿元，同比下降41.94%；其中2025年第三季度，公司单季度主 营收入9.61亿元，同比下降18.95%；单季度归母净利润-1.29亿元，同比下降234.24%；单季度扣非净利 润-1.23亿元，同比下降52.03%；负债率68.8%，投资收益2075.86万元，财务费用1.11亿元，毛利率 6.59%。 ...

智通财经APP讯，国际医学(000516.SZ)披露2025年度业绩预告，公司预计归属于上市公司股东的净亏损 2.95亿元至3.15亿元;扣除非经常性损益后的净亏损3.2亿元至3.5亿元。 ...

报告期内，公司受市场波动、DRG支付政策改革等行业动态调整影响，营业收入同比下降。公司采取 调整业务结构，实施降本增效等措施并持续改善经营成效，第四季度亏损幅度收窄，但营业收入总规模 尚未能覆盖运营成本和期间费用。 国际医学2025年三季报显示，前三季度公司主营收入29.95亿元，同比下降16.94%；归母净利润-2.94亿 元，同比下降38.45%；扣非净利润-3.12亿元，同比下降41.94%；其中2025年第三季度，公司单季度主 营收入9.61亿元，同比下降18.95%；单季度归母净利润-1.29亿元，同比下降234.24%；单季度扣非净利 润-1.23亿元，同比下降52.03%；负债率68.8%，投资收益2075.86万元，财务费用1.11亿元，毛利率 6.59%。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，国际医学发布业绩预告，预计2025年全年扣非后净利润亏损3.2亿元至3.5亿元。 公告中解释本次业绩变动的原因为： ...